UPCC 17525: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Investigating Treatment Options for Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer

Enrolling By Invitation
18 years or above
All
Phase 2/3
500 participants needed
1 Location

Brief description of study

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Small Cell Lung Cancer
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Non-squamous NSCLC, not amenable to treatment in curative intent.
  • Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
  • Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
  • Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed).

Exclusion criteria:

  • Inadequate organ function and/or bone marrow reserve.
  • Leptomeningeal metastases or spinal cord compression.
  • Poorly controlled systemic medical conditions.
  • Other protocol-defined inclusion/exclusion criteria apply.

This study investigates treatment options for patients with non-small cell lung cancer (NSCLC) that have mutations in the epidermal growth factor receptor (EGFR) gene. Patients in this study have experienced disease progression despite previous treatment with EGFR tyrosine kinase inhibitors, which are medications that block signals promoting cancer cell growth.

Participants in this study will be randomly assigned to receive either the investigational medication or a standard chemotherapy treatment using platinum-based drugs combined with pemetrexed. The study will monitor the effects of these treatments on cancer progression and overall health. Participants will undergo regular assessments to evaluate the safety and effectiveness of the treatments.

  • Who can participate: Adults with non-squamous NSCLC that is not treatable with curative intent and who have specific EGFR mutations are eligible. Participants must have experienced disease progression after treatment with a third-generation EGFR-TKI and be suitable for platinum-based chemotherapy.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a chemotherapy regimen. The chemotherapy involves platinum-based drugs and pemetrexed. Regular health assessments will be conducted to monitor treatment effects.
Updated on 22 Jun 2026. Study ID: 25-1754
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator